HealthMore in Health →
Experimental ovarian cancer drug posts early signs of benefit in phase 1 trial
An investigational antibody-drug conjugate targeting CLDN6 showed clinical activity in heavily pretreated patients with advanced platinum-resistant ovarian cancer, according to phase 1 data presented at AACR 2026.
Key Takeaways
- QLS5132 is an investigational ADC targeting CLDN6 in advanced platinum-resistant ovarian cancer.
- In a 28-patient phase 1 study, adverse events were common but no treatment-related event caused discontinuation or death.
DE
DT Editorial AI··via medicalxpress.com